This review highlights the controversial but significant association between maternal thrombophilia and adverse pregnancy outcomes, discussing potential prophylactic and therapeutic strategies.
Thrombophilia screening or prophylaxis in pregnancy should not yet change practice; leaves open need for definitive RCTs to resolve ongoing controversy.
Thrombophilias are inherited or acquired conditions that predispose an individual to thromboembolism. During pregnancy, maternal thrombophilia has been identified as a major risk factor for adverse pregnancy outcomes (APO), including venous and arterial thrombosis, preeclampsia, placental abruption, intrauterine growth restriction, intrauterine fetal losses and recurrent miscarriages. Although a great body of evidence has accumulated regarding this association, there is still much controversy. In this review, aspects of certain APO and thrombophilia are discussed, as well as prophylactic and therapeutic implications.
No takes yet. Share an insight, caveat, or question.
Weintraub et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: